EP Patent

EP2752191A1 — Compositions and methods using hdm2 antagonist and mek inhibitor

Assigned to Sanofi SA · Expires 2014-07-09 · 12y expired

What this patent protects

Methods of causing growth inhibition of cancer cells are provided, wherein the methods comprise contacting cancer cells with an HDM2 antagonist and a MEK inhibitor. Compositions in which the HDM2 antagonist and MEK inhibitor are combined also are provided.

USPTO Abstract

Methods of causing growth inhibition of cancer cells are provided, wherein the methods comprise contacting cancer cells with an HDM2 antagonist and a MEK inhibitor. Compositions in which the HDM2 antagonist and MEK inhibitor are combined also are provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP2752191A1
Jurisdiction
EP
Classification
—
Expires
2014-07-09
Drug substance claim
No
Drug product claim
No
Assignee
Sanofi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.